Work

Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-149366

Authors: Tara L. Lin, Justin M Watts, Alice S. Mims, Prapti Patel, Paul J Shami, Elizabeth H. Cull, Christopher R. Cogle, Cynthia Lee, Fatih Uckun

Institutions: University of Kansas, University of Miami Health System, Sylvester Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, The University of Texas Southwestern Medical Center, University of Utah, Huntsman Cancer Institute, Prisma Health, University of Florida, Aptevo Therapeutics (United states)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3214138253

Cites:

Cited by: 1

Related to: 10